Literature DB >> 25332596

Acquired factor v inhibitor developing after treatment with dabigatran etexilate methanesulfonate: a case report and review of the literature.

Yasunobu Sekiguchi1, Hitomi Yoshikawa1, Asami Shimada1, Hidenori Imai1, Mutsumi Wakabayashi1, Keiji Sugimoto1, Noriko Nakamura2, Tomohiro Sawada2, Tetsuo Ichinose3, Dai Ozaki4, Norio Komatsu1, Masaaki Noguchi1.   

Abstract

A 90-year-old man presented with subcutaneous ecchymoses. He had been under treatment with dabigatran etexilate methanesulfonate (DEM). Prolonged APTT and decreased PT was developed 2 months after the start of DEM, more prolonged 6 months later. DEM was discontinued, the coagulopathy did not improve. Factor V activity was decreased, along with appearance of coagulation factor V inhibitor (FVI). He did not have antiphospholipid syndrome or malignancy. He was diagnosed as having acquired FVI caused by DEM. Steroid pulse therapy was effective. There have been 74 reported cases of AFVI induced by drug treatment, but none after treatment with DEM.

Entities:  

Keywords:  Acquired factor V inhibitor; Coagulation factor V deficiency; Dabigatran etexilate methanesulfonate; Steroid pulse

Year:  2014        PMID: 25332596      PMCID: PMC4192195          DOI: 10.1007/s12288-014-0358-4

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  11 in total

Review 1.  Clinical and laboratory manifestations of anti-factor V antibodies.

Authors:  T L Ortel
Journal:  J Lab Clin Med       Date:  1999-04

2.  [Isolated factor V deficiency caused by a specific inhibitor].

Authors:  M H HORDER
Journal:  Acta Haematol       Date:  1955-04       Impact factor: 2.195

3.  A case report of an acquired inhibitor to coagulation factor V.

Authors:  H Shanmugam; S Jayaranee; G I Eow
Journal:  Haemophilia       Date:  2011-01       Impact factor: 4.287

4.  Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation.

Authors:  Emmanuel J Favaloro; Jennifer Posen; Raj Ramakrishna; Soma Soltani; Simon McRae; Sarah Just; Margaret Aboud; Joyce Low; Rosalie Gemmell; Geoff Kershaw; Robyn Coleman; Mark Dean
Journal:  Blood Coagul Fibrinolysis       Date:  2004-10       Impact factor: 1.276

5.  Acquired factor V inhibitor complicating warfarin therapy.

Authors:  Benjamin Gartrell
Journal:  Am J Hematol       Date:  2011-08       Impact factor: 10.047

6.  Acquired factor V inhibitor in a patient with a mechanical aortic valve under warfarin therapy.

Authors:  Tsukasa Nozu; Hiroaki Mita; Toshikatsu Okumura
Journal:  Intern Med       Date:  2010-10-15       Impact factor: 1.271

Review 7.  Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.

Authors:  Michael B Streiff; Paul M Ness
Journal:  Transfusion       Date:  2002-01       Impact factor: 3.157

8.  Acquired factor V inhibitor responsive to corticosteroids in a patient with double cancers.

Authors:  Hitoshi Endo; Kiyotaka Kawauchi; Masahiko Tomimatsu; Daijiro Iga; Toshie Ogasawara; Masako Yasuyama; Toshihito Saito; Kuniaki Otsuka; Motohiko Aiba
Journal:  Intern Med       Date:  2007-05-01       Impact factor: 1.271

Review 9.  Acquired factor V inhibitor. A problem-based systematic review.

Authors:  Ai Leen Ang; Ponnudurai Kuperan; Chin Hin Ng; Heng Joo Ng
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

10.  In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.

Authors:  Wolfgang Wienen; Jean-Marie Stassen; Henning Priepke; Uwe Joerg Ries; Norbert Hauel
Journal:  Thromb Haemost       Date:  2007-07       Impact factor: 5.249

View more
  2 in total

1.  Acquired Factor V Inhibitor.

Authors:  Daisuke Hirai; Yugo Yamashita; Nobutoyo Masunaga; Toshiaki Katsura; Masaharu Akao; Yoshiaki Okuno; Hiroshi Koyama
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

2.  Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease.

Authors:  Eisuke Katsuren; Kentaro Kohagura; Takanori Kinjyo; Ryo Zamami; Takuto Nakamura; Nanako Oshiro; Yoshitsugu Sunagawa; Kumiko Omine; Yuki Kudo; Yuki Shinzato; Tsukasa Osaki; Masayoshi Souri; Akitada Ichinose; Masanobu Yamazato; Akio Ishida; Yusuke Ohya
Journal:  CEN Case Rep       Date:  2022-08-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.